Seemal Desai, M.D., FAAD, discusses how immune system dysregulation and genetic variants intersect to trigger vitiligo development while highlighting diagnostic challenges including identifying disease subtypes and distinguishing vitiligo from other depigmentation disorders.
The panelist discusses how emerging targeted therapies like Janus kinase inhibitors and combination treatment approaches are transforming vitiligo management, with treatment selection guided by disease patterns, progression rates and individual patient response, while acknowledging the need for systematic assessment and alternative strategies for treatment-resistant cases.
Seemal Desai, M.D., FAAD, discusses how treatment safety and effectiveness must be carefully evaluated through monitoring clinical outcomes and patient-reported measures, with special consideration given to unique challenges in vulnerable populations like children, pregnant women and those with comorbidities, where treatment approaches require careful modification to balance efficacy and safety concerns.
Seemal Desai, M.D., FAAD, discusses how managed care organizations can improve access to advanced vitiligo treatments through updated formulary decisions and treatment algorithms while addressing insurance coverage barriers and balancing treatment aggressiveness with value-based care considerations.
The panelist discusses how vitiligo’s psychological and social impacts significantly affect patients’ quality of life and treatment adherence, necessitating a holistic approach that addresses both physical symptoms and psychosocial support needs.
Seemal Desai, M.D., FAAD, discusses how effective patient education and engagement strategies, combined with emerging telemedicine and digital health technologies, enhance vitiligo care delivery, disease monitoring and patient self-management capabilities.
